News & Analysis as of

Transparency Research and Development

Gardner Law

FDA Highlights the Promise of AI in Healthcare

Gardner Law on

On June 17, 2024, the U.S. Food and Drug Administration’s (FDA) Digital Health Center of Excellence (DHCE), published a blog article highlighting the promise of artificial intelligence (AI) in healthcare. In the article, the...more

White & Case LLP

AI Watch: Global regulatory tracker - OECD

White & Case LLP on

The OECD's AI recommendations encourage Member States to uphold principles of trustworthy AI. Laws/Regulations directly regulating AI (the “AI Regulations”) The OECD's Recommendation of the Council on Artificial...more

Foley & Lardner LLP

Equal Employment Opportunity Commission Goes After Employers Who Failed to File EEO-1 Reports

Foley & Lardner LLP on

The EEO-1 report, mandated by Title VII of the Civil Rights Act of 1964, requires private employers with 100 or more employees, as well as employers who contract with the federal government with 50 or more employees and...more

ArentFox Schiff

Continuing Forward: Senate Leaders Release an AI Policy Roadmap

ArentFox Schiff on

The US Senate’s Bipartisan AI Policy Roadmap is a highly anticipated document expected to shape the future of artificial intelligence (AI) in the United States over the next decade. This comprehensive guide, which complements...more

Mintz - Antitrust Viewpoints

Senate Leadership Releases Sweeping AI Policy Agenda Calling for $32 Billion in R&D Funding — AI: The Washington Report

The Bipartisan Senate AI Working Group, headed by Majority Leader Chuck Schumer (D-NY), Senator Mike Rounds (R-SD), Senator Martin Heinrich (D-NM), and Senator Todd Young (R-IN) released a roadmap for congressional AI policy....more

TransPerfect Legal

GDPR Compliance: At the Intersection of AI and Life Sciences

TransPerfect Legal on

Late last month, the Association of Corporate Counsel (ACC) hosted a panel on artificial intelligence and how it is rapidly transforming the life sciences sector, allowing companies to leverage large datasets to accelerate...more

Hanzo

Spotlight AI: The story behind the feature

Hanzo on

Rethink Everything! Hanzo's journey in AI actually began well before the recent unveiling of Spotlight AI last week and the announcement that Hanzo won the the LegalTechnology Breakthrough Award for best use of AI technology...more

Rothwell, Figg, Ernst & Manbeck, P.C.

Regulating AI: An Overview of Federal Efforts

This first part of a two-part series on U.S. regulation of artificial intelligence systems provides an overview and modern context for the existing regulatory, legal and risk management landscape for AI systems in the U.S.,...more

Cooley LLP

Drug Price Transparency Bill Enacted in Oregon

Cooley LLP on

The Governor of Oregon signed into law this week House Bill 4005, the Prescription Drug Price Transparency Act (Act). The Act requires manufacturers to report by March 31st each year information regarding each prescription...more

McDermott Will & Emery

21st Century Cures: A Closer Look

McDermott Will & Emery on

On December 7, 2016, the US Congress enacted the 21st Century Cures Act, substantial legislation intended to accelerate “discovery, development and delivery” of medical therapies by encouraging biomedical research investment,...more

King & Spalding

White House Releases National Privacy Research Strategy

King & Spalding on

On July 1, James Kurose, the Assistant Director for Computer and Information Science and Engineering Directorate at the National Science Foundation, and Keith Marzullo, the Director of the National Coordination Office for...more

Mintz - ML Strategies

Transparency in Drug Pricing: Issues to Consider from the Research Lab to the Consumer

Mintz - ML Strategies on

Since 2014, drug pricing has grown in importance in health care policy conversations. From Gilead Sciences’s Hepatitis C treatment costing $84,000 per course of treatment to Turing Pharmaceutical’s 5,000 percent price hike of...more

Mintz - Health Care Viewpoints

States Step Up Efforts on Drug Pricing Initiatives

A few months ago, we noted that states were jumping into the drug pricing fray largely driven by a lack of federal action and a rising tide of public discontent. State legislation has taken various forms but most of the...more

13 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide